Among the compounds for targeting the TNF-α/NF-κB pathway, firstly, isoliquiritigenin was previously demonstrated for attenuating myocardial ischemia reperfusion injury and inhibiting the activity of TNF-α(Chi et al., 2017; Yushan et al., 2018; Yao et al., 2022). Here, TNF is linked to myocardial ischemia.